Xoma | XOMA - Cost Of Sales


Xoma reported 116K in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Agenus USD 642K 399K Sep/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Ardelyx USD 10.85M 6.87M Dec/2025
aTyr Pharma USD 3.34M 18.79M Dec/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
Curis USD 314K 9.96M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Incyte USD 121.18M 22.18M Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Novartis USD 3.54B 7M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Xoma 116K 112.7K Jun/2024